Characteristics of FVIII inhibitor patients were similar to our first report [6]: median age at inhibitor development (47.5 vs 35.3 with overlapping IQR), proportion with moderate hemophilia (42 vs 36%), and 58% vs 72% developing within the first 50 EDs. This evidence concerns the gene F8 and hemophilia.